Obexelimab
Phase 3Monoclonal antibody
Obexelimab is one of 80 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Obexelimab
ZZenas BioPharma (USA), LLC
Phase 3
Betaseron
BayerPreclinical
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Avonex
EMD SeronoPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Zinbryta
RochePreclinical
Flomax
SanofiPreclinical
Pred Forte
NovartisPreclinical
Myfortic
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Warm Autoimmune Hemolytic Anemia1 trial
Systemic Lupus Erythematosus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Obexelimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZenas BioPharma (USA), LLC